Arbutus Biopharma (ABUS) Preferred Shares (2017 - 2021)

Arbutus Biopharma (ABUS) has reported Preferred Shares for 5 consecutive years, with $161.0 million the latest figure, recorded in Q3 2021.

• Quarterly Preferred Shares rose 10.04% year-over-year to $161.0 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $161.0 million (up 10.04% YoY) and the FY2020 annual result came in at $149.4 million, up 8.83% from the prior year.
• Preferred Shares improved to $161.0 million in Q3 2021 per ABUS's latest filing, from $155.9 million in the prior quarter.
• Over the last five years, Preferred Shares for ABUS reached as high as $161.0 million in Q3 2021 and fell as low as $49.8 million in Q4 2017.
• A 5-year average of $132.5 million and a median of $135.8 million in 2019 frame the typical range for Preferred Shares.
• Annual changes were most pronounced in 2018 — Preferred Shares surged 153.39% — and 2021, when it rose 8.81%.
• Year by year, Preferred Shares stood at $49.8 million in 2017, then jumped by 153.39% to $126.1 million in 2018, then grew by 8.84% to $137.3 million in 2019, then grew by 8.83% to $149.4 million in 2020, then increased by 7.74% to $161.0 million in 2021.
• According to Business Quant data, Preferred Shares over the past three periods registered $161.0 million, $155.9 million, and $152.6 million for Q3 2021, Q2 2021, and Q1 2021 respectively.